SGLT2 inhibitors: a review of their antidiabetic, renoprotective, and cardioprotective effects

doi:10.3877/cma.j.issn.2095-3216.2020.01.003

Abstract

Abstract:

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of hypoglycemic agents that have emerged in recent years. Their unique mechanism of action, good hypoglycemic effect, prominent cardial-renal protection and minor side effects are getting more and more attention. SGLT2 inhibitors act on SGLT2 that are distributed in the proximal tubules of the kidney, inhibiting the reabsorption of glucose, thereby exerting a hypoglycemic effect. In addition, SGLT2 inhibitors also protect the heart and kidneys through a series of mechanisms that are not dependent on hypoglycemic effects. At present, many results published or of ongoing randomized controlled trials have demonstrated that SGLT2 inhibitors had significant cardioprotective and renoprotective effect. This article reviewed the mechanism of SGLT2 inhibitors in blood glucose control, cardioprotective effect, renoprotective effect, and adverse reactions.

Key words: Diabetes, Sodium-glucose cotransporter 2 inhibitors, Glycemic control, Renoprotective, Cardioprotective

Nan Ye, Hong Cheng. SGLT2 inhibitors: a review of their antidiabetic, renoprotective, and cardioprotective effects[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(01): 12-16.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.01.003

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I01/12

References 49

[1]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志， 2018, 10(1): 4-67.
[2]	American Diabetes Association. Improving care and promoting health in populations: standards of medical care in diabetes-2019 [J]. Diabetes Care, 2019, 42(Suppl 1): S7-S12.
[3]	American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2019 [J]. Diabetes Care, 2019, 42(Suppl 1): S103-S123.
[4]	Cavender MA, Steg PG, Smith SC Jr, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry [J]. Circulation, 2015, 132(10): 923-931.
[5]	McAllister DA RS, Kerssens J, Livingstone S, et al. Incidence of hospitalisation for heart failure and case-fatality among 3.25 million people with and without diabetes [J]. Circulation, 2018, 138(24): 2774-2786.
[6]	Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014 [J]. JAMA, 2016, 316(6): 602-610.
[7]	American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2019 [J]. Diabetes Care, 2019, 42(Suppl 1): S124-S138.
[8]	Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis [J]. Lancet, 2012, 380(9854): 1662-1673.
[9]	Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus [J]. Annu Rev Med, 2015, 66: 255-270.
[10]	Roder PV, Geillinger KE, Zietek TS, et al. The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing[J]. PLoS One, 2014, 9(2): e89977.
[11]	Norton L, Shannon CE, Fourcaudot M, et al. Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects [J]. Diabetes Obes Metab, 2017, 19(9): 1322-1326.
[12]	Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review [J]. Int J Endocrinol Metab, 2019, 17(2): e84353.
[13]	Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review [J]. Diabetologia, 2018, 61(10): 2108-2117.
[14]	Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure [J]. JAMA Cardiol, 2017, 2(9): 939-940.
[15]	Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials [J]. Circulation, 2017, 136(17): 1643-1658.
[16]	Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial [J]. Diabetes Care, 2018, 41(2): 356-363.
[17]	Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis [J]. Diabetes Obes Metab, 2018, 20(3): 479-487.
[18]	Striepe K, Jumar A, Ott C, et al. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus [J]. Circulation, 2017, 136(12): 1167-1169.
[19]	Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2015, 17(12): 1180-1193.
[20]	Li H, Shin SE, Seo MS, et al. The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels [J]. Life Sci, 2018, 197: 46-55.
[21]	Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study [J]. Cardiovasc Diabetol, 2017, 16(1): 138.
[22]	Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis [J]. Diabetes Care, 2016, 39(7): 1108-1114.
[23]	Lopaschuk GD, Verma S. Empagliflozin's fuel hypothesis: not so soon [J]. Cell Metab, 2016, 24(2): 200-202.
[24]	Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action [J]. JAMA Cardiol, 2017, 2(9): 1025-1029.
[25]	Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na^＋/H^＋ exchanger, lowering of cytosolic Na^＋ and vasodilation [J]. Diabetologia, 2018, 61(3): 722-726.
[26]	Baartscheer A, Schumacher CA, Wüst RC, et al. Empagliflozin decreases myocardial cytoplasmic Na^＋ through inhibition of the cardiac Na^＋/H^＋ exchanger in rats and rabbits [J]. Diabetologia, 2017, 60(3): 568-573.
[27]	Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts [J]. Free Radic Biol Med, 2017, 104: 298-310.
[28]	Packer M. Do sodium-glucose cotransporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis [J]. Diabetes Obes Metab, 2018, 20(6): 1361-1366.
[29]	Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes [J]. Metabolism, 2018, 85: 32-37.
[30]	Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume [J]. Cardiovasc Diabetol, 2018, 17(1): 6.
[31]	Zatz R DB, Meyer TW, Anderson S, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension [J]. J Clin Invest, 1986, 77(6): 1925-1930.
[32]	Heerspink HJ, Kropelin TF, Hoekman J, et al. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis [J]. J Am Soc Nephrol, 2015, 26(8): 2055-2064.
[33]	Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications [J]. Circulation, 2016, 134(10): 752-772.
[34]	Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects [J]. J Am Soc Nephrol, 2017, 28(1): 368-375.
[35]	Brown E, Rajeev SP, Cuthbertson DJ, et al. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors [J]. Diabetes Obes Metab, 2019, 21(Suppl 2): 9-18.
[36]	Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial [J]. Lancet Diabetes Endocrinol, 2017, 5(8): 610-621.
[37]	Dekkers CCJ, Petrykiv S, Laverman GD, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers [J]. Diabetes Obes Metab, 2018, 20(8): 1988-1993.
[38]	Sun YN, Zhou Y, Chen X, et al. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials [J]. BMJ Open, 2014, 4(4): e004619.
[39]	Yang T, Lu M, Ma L, et al. Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis [J]. Eur J Clin Pharmacol, 2015, 71(11): 1325-1332.
[40]	Häring HU ML, Seewaldt-Becker E, Weimer M, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial [J]. Diabetes Care, 2014, 37(6): 1650-1659.
[41]	Aronson R, Frias J, Goldman A, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study [J]. Diabetes Obes Metab, 2018, 20(6): 1453-1460.
[42]	Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [J]. N Engl J Med, 2019, 380(24): 2295-2306.
[43]	Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes [J]. N Engl J Med, 2016, 375(4): 323-334.
[44]	Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials [J]. Lancet Diabetes Endocrinol, 2018, 6(9): 691-704.
[45]	Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes [J]. N Engl J Med, 2019, 380(4): 347-357.
[46]	Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis [J]. Lancet Diabetes Endocrinol, 2019, 7(11): 845-854.
[47]	Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes [J]. N Engl J Med, 2015, 373(22): 2117-2128.
[48]	Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes [J]. N Engl J Med, 2017, 377(7): 644-657.
[49]	McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction [J]. N Engl J Med, 2019, 381(21): 1995-2008.

Please choose a citation manager

Content to export